Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health
Received: 22 April 2020
Revised: 12 August 2020
Accepted: 26 August 2020
First Online: 14 September 2020
Ethics approval and consent to participate
: Mouse protocols adhered to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Review Committees at SBP, at Advanced Industrial Science and Technology (AIST), and at Kyoto University. No human subject is involved in this study.
: All data supporting the results reported in the article are available upon request.
: M.N.F. is the founder of IF7CURE, INC., a company with development rights around the peptide IF7C(RR)-SN38 reported in this study. Other authors declare no potential conflicts of interest.
: This study was supported by National Cancer Institute grant P01 CA71932, by an institutional AIST grant LEAD, by the Project for Cancer Research and Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research and Development (AMED) to M.N.F., by P41 GM103390 and P41 RR005351, and by a Research Grant for Young Japanese Scientists from The Nakajima Foundation to M.N.